profit from every $100 of sales.
$0$100
Talphera
$1.05+0.00% today
-18.6% in 1 year
1-year low $0.721-year high $1.47
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Talphera sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $28,000 in 2025, with -$14.3 million of profit last year.
SalesProfit
Talphera vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Talphera | No profit yet | ||
 Merck KGaA | 25.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Talphera's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 1 | 0 | 0 | |
| -1 | – | – | – | |
| -20 | -17 | -15 | -13 | |
| 62 | -10 | -13 | -14 | |
| 48 | -18 | -13 | -14 | |
| 5.72 | -1.29 | -0.50 | -0.34 | |
| – | – | – | – | |
| – | -2,594.3% | – | -48,157.1% | |
| – | -2,826.0% | – | -51,035.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 47 | 20 | 18 | 30 |
| Cash | 15 | 6 | 9 | 6 |
| Total debt | 5 | – | – | – |
| Total liabilities | 26 | 6 | 10 | 13 |
| 22 | 14 | 8 | 17 | |
| 7 | 14 | 26 | 42 | |
| 175.2% | -56.9% | -124.5% | -66.6% | |
| 218.9% | -130.4% | -162.5% | -83.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -28 | -17 | -13 | -11 | |
| 0 | 0 | – | – | |
| -29 | -18 | -13 | -11 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | – | – | |
| 3 | 2 | 1 | 1 |
Valuation
- –
- –
- –
- 2.3×
- 1,946.5×
- –
- –
- -20.9%
- -26.2%
- 0.0%
Profitability
- -4,075.0%
- -48,157.1%
- -51,035.7%
- -40,635.7%
- -52.0%
- 11.2%
- -118.0%
- -48.1%
- -52.0%
- 21,546.4%
Growth
- −79.3%
- –
- +10.4%
- –
- +63.1%
Financial health
- -0.4×
- 0.38
- 21.9%
- –
- 5.49
- 5.49
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 958
Bottom 1%of 889
Bottom 4%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.04 | -0.07 | +42.9% |
| Mar 23, 2026 | -0.06 | -0.08 | +20.0% |
| Nov 12, 2025 | -0.11 | -0.08 | −46.7% |
| Aug 14, 2025 | -0.10 | -0.12 | +16.7% |
| May 13, 2025 | -0.16 | -0.17 | +5.9% |
| Mar 31, 2025 | -0.07 | -0.21 | +66.7% |
| Nov 13, 2024 | -0.13 | -0.20 | +35.0% |
| Aug 14, 2024 | -0.15 | -0.22 | +31.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
47No pass
Philip Fisher
43No pass
Peter Lynch
5No pass
Joel Greenblatt
0No pass
Charlie Munger
40No pass
Terry Smith
37No pass
Questions about Talphera
Is Talphera a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Talphera AI analysis
What does Talphera do?
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. It is in Drug Manufacturers - Specialty & Generic.
Does Talphera pay a dividend?
No. Talphera does not pay a dividend at the moment.
Is Talphera stock halal?
Questionable. Talphera sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Talphera stock done over the past year?
Down 18.6% over the past twelve months, to $1.05. It traded between $0.72 and $1.47 and is 28.6% below its high.
Who are Talphera's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Talphera's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.